Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Next Previous
Trial Profile

A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZODIAC
  • Sponsors AstraZeneca; Sanofi Genzyme

    • Most Recent Events

    • 17 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Jul 2010 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2010 Staus change from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top